JAV dd
Javelin Pharmaceuticals Signs Commercial Supply Agreement with Precision Pharma Services
2/26/2007 9:20:22 AM
New York-Based Contract Manufacturer to Supply Dyloject(TM) for Launch in Europe
CAMBRIDGE, Mass., Feb 26, 2007 (BUSINESS WIRE) -- Javelin Pharmaceuticals, Inc. ( JAV ), a leading developer of novel products for pain control, today announced it has signed a Commercial Supply Agreement with Precision Pharma Services, Inc. Under the Agreement, Precision will manufacture vials of Javelin's injectable Dyloject(TM) product (diclofenac sodium 75mg / 2mL) for use in Javelin's anticipated European markets pending regulatory approval. The Agreement has a two-year, renewable term and sets forth minimum purchase and production requirements.
"This agreement is an important step forward in growing Javelin's manufacturing infrastructure in anticipation of initial product sales later this year in Europe," said Michael Moshman, Javelin's Vice President for Clinical and Commercial Manufacturing. "Working with Precision Pharma will enable us to marshal the resources to meet future demand for Dyloject as we begin commercializing this promising analgesic with its launch in the UK in 2007."
About Javelin Pharmaceuticals, Inc.
With US corporate headquarters in Cambridge, MA, and a European office in Cambridge, UK, Javelin applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs to target unmet and underserved medical needs in the pain management market. For additional information, please visit the website at www.javelinpharmaceuticals.com.
About Precision Pharma Services, Inc.
Pr
News 
Market Data 
Discover 
